Kozielewicz Dorota, Halota Waldemar, Dybowska Dorota
Klinika Chorób Zakaźnych i Hepatologii, Collegium Medicum im. L.Rydygiera w Bydgoszczy UMK w Toruniu.
Przegl Epidemiol. 2012;66(1):49-54.
Since ten years pegylated interferon alpha and ribavirin (PR) are a standard treatment for the patients with chronic HCV infection. Recently, new drugs emerge called direct-acting antivirals. The first of them, telaprevir (TVR) and boceprevir (BOC), which peptidomimetic NS3/4A HCV serine protease inhibitors, have been recorded this year in Europe. Adding them to the PR significantly increases efficacy of standard treatment and creates the possibility of its reduction. This paper presents, based on the results of the third phase studies, the efficacy of triple therapy in selected groups of patients. Also includes current recommendations for treatment with BOC or TVR in combination with PR.
十年来，聚乙二醇化干扰素α和利巴韦林（PR）一直是慢性丙型肝炎病毒（HCV）感染患者的标准治疗方案。最近，出现了一类名为直接抗病毒药物的新药。其中第一种，替拉瑞韦（TVR）和博赛匹韦（BOC），作为肽模拟物NS3/4A HCV丝氨酸蛋白酶抑制剂，已于今年在欧洲上市。将它们添加到PR方案中可显著提高标准治疗的疗效，并有可能缩短疗程。本文基于三期研究结果，介绍了三联疗法在特定患者群体中的疗效。还包括目前关于BOC或TVR与PR联合治疗的建议。
